患者來源異種移植模型市場分析及預測（至2035年）：依類型、產品類型、小鼠模型、服務、應用、最終使用者及技術分類

預計到2035年，患者來源異種移植模型（PDX）市場規模將從2025年的3.637億美元成長至11.219億美元，年複合成長率約為12.1%。腫瘤研發需求的不斷成長主要源自於製藥和生技公司對預測性臨床前模型的強勁需求。各公司尋求多樣化的PDX模型（固態腫瘤、血液腫瘤和兒童腫瘤），以進行轉化研究和治療評估。例如，Charles River提供超過1700種PDX模型，涵蓋45種以上的癌症適應症，以支持多種腫瘤類型的藥物療效測試。

特殊模型供應 - PDX模型供應有限，尤其是低代次腫瘤、罕見癌症類型和人源化平台。供體組織來源和移植成功率的挑戰限制了產能。例如，Crown Bioscience的HSC-PDX和Hera Biolabs的MiXeno™ PBMC人源化模型需求量大，但供應有限。

法規遵從性和資料可靠性 - 市場對能夠維持高遺傳和組織學保真度、提供可重複結果並符合監管標準的PDX模型有著強烈的需求。具備這些特性的模式是IND申報和轉化研究的首選。例如，Oncodesign和Charles River提供特徵明確的PDX模型，確保其臨床相關性和法規遵循。

技術進步和自動化 - 例如人工智慧、成像技術和基於類器官的體外檢測方法的引進 - 提高PDX研究的預測準確性和效率。例如，查爾斯河實驗室的人工智慧驅動的虛擬控制和3D類器官PDX平台可以加速臨床前試驗，並減少對動物模型的依賴。

細分市場概覽

根據腫瘤類型，患者來源的異種移植（PDX）模型市場分為消化器官系統腫瘤、呼吸系統腫瘤、婦科腫瘤、骨髓惡性腫瘤、中樞神經系統腫瘤、皮膚腫瘤和其他固態腫瘤。

由於肺癌在全球造成的巨大負擔，呼吸腫瘤學領域是成長最快的領域之一。預計到2022年，肺癌新增病例將達到約 248萬例，使其成為全球最常見的癌症，也是癌症死亡的主要原因。

這種高發病率推動了非小細胞肺癌（NSCLC）研究領域對 PDX 模型的強勁需求，以探索驅動突變和抗藥性機制。例如，2024年，倫敦大學學院（UCL）的研究人員透過 CancerTools.org 註冊了 44個 NSCLC TRACERx PDX 模型，能夠研究腫瘤演變、異質性、免疫逃脫和抗藥性，滿足了肺癌轉化研究領域對 PDX 模型日益成長的需求。

胃腸腫瘤學也是 PDX 應用的主要推動因素，2022年結直腸癌在全球排名第三（約 193萬新病例），胰腺癌記錄了約 510,992 例新病例，這兩種疾病都存在顯著的未滿足臨床需求，而 PDX 平台比傳統模型更能保留腫瘤異質性，因此將使這兩種疾病受益。

胃腸腫瘤領域的發展得益於臨床相關PDX模型的日益普及，這些模型能夠進行高保真度的臨床前研究。其中的關鍵進展包括Champion Oncology的胃癌PDX模型（保留了患者腫瘤的生物學特性）以及Crown Bioscience的龐大胃腸道PDX模型庫（涵蓋結直腸癌和胃癌）。

此外，Charles River Laboratories在2019年新增了79種消化器官系統PDX模型，The Jackson Laboratory也擁有經臨床檢驗的消化器官系統產品組合，這些都為藥物篩檢和生物標記研究提供了強大的平台。這些資源加速轉化研究，支持精準腫瘤學研發管線，並推動該領域的強勁成長。

由於迫切需要能夠重現人類白血病、淋巴瘤和多發性骨髓瘤生物學特徵的模型，骨髓惡性腫瘤推動PDX市場的成長。諸如Crown Bioscience的急性骨髓性白血病（AML）模型庫（2017年）以及華盛頓大學PDX開發與測試中心（2025年，Siteman癌症中心）龐大的血液學PDX模型庫等PDX平台，能夠支持臨床前藥物測試、抗藥性機制研究和個人化治療評估。

地理概覽

由於癌症負擔呈指數級成長，以及由此產生的對可預測的、與患者相關的臨床前模型的需求，北美患者來源異種移植（PDX）模型市場擴張。預計到2024年，美國將報告約2,001,140例新增癌症病例和611,720例癌症死亡病例，反映出人口老化、診斷覆蓋率提高和篩檢率上升所導致的創紀錄的高發病率。所有這些都推動了對更生物學精確性的癌症研究模型的需求。

美國在北美PDX模型市場佔據最大佔有率，這得益於其龐大的生物製藥研發生態系統、專業的受託研究機構（CRO）以及在腫瘤領域雄厚的研發投入。根據美國科學與工程統計中心（NCSES）的資料顯示，美國企業在2023年將投入約7,220億美元用於研發，其中430億美元（6%）將用於基礎研究，1,100億美元（15%）將用於應用研究，顯示美國持續重視研發投入，以支持對PDX模型等轉換平台的需求。

預計亞太地區將在預測期內成為成長最快的地區。由於癌症負擔沉重以及腫瘤學研究的不斷深入，該地區的患者來源異種移植（PDX）模型市場快速成長。根據Pfizer公司統計，亞洲主要國家約有360萬男性和400萬女性罹患癌症，其中光是中國就有160萬男性和150萬女性。中國已建立了用於胃腸道癌、肺癌、肝癌和食道癌的大規模PDX模型庫，能夠精確地保留腫瘤組織學特徵和藥物反應性。

在日本，J-PDX Library、福島醫科大學和金澤大學等高校利用乳癌、白血病、胰臟癌和兒童急性淋巴性白血病（ALL）的PDX模型來支持個人化醫療和藥物試驗。印度崛起為PDX研究中心，其中ACTREC開發三陰性乳癌（TNBC）和荷爾蒙受體陽性乳癌的模型，TheraIndx提供PDX/CDX模型，而Altogen Labs計劃於2024年8月檢驗10種肺癌異種移植模型。

在澳洲，兒童癌症研究所、MURAL、新南威爾斯大學雪梨分校、WEHI 和Peter MacCallum癌症中心使用前列腺癌、乳癌、大腸直腸癌和兒童癌症的PDX模型。在韓國，CHA Bundang醫療中心和Yonsei University Severance Hospital引進卵巢、胃癌和膽道癌的PDX模型。

在新加坡，NCCS、A*STAR IMCB、NUS利用這些模型進行肝癌和膽道癌研究。印尼開發用於乳癌和其他固態腫瘤的PDX模型，以支持轉化研究。在全部區域，這些努力反映了癌症發生率的上升以及與患者相關的臨床前模型的應用，推動了對PDX模型的強勁需求。

主要趨勢和促進因素

「PDX模型外包給CRO的增加加速市場擴張」

將臨床前腫瘤研究外包給受託研究機構（CRO）的做法推動市場成長。隨著製藥和生技公司不斷拓展其研發管線，它們本身的研發能力已接近極限，因此越來越傾向於尋求擁有專業PDX（患者來源異種移植）能力的合作夥伴。

透過外包給合約研究組織（CRO），申辦方可以獲得許多內部實驗室所缺乏的專業知識、基礎設施和可擴展的動物飼養資源，同時降低成本並縮短轉化研究週期。例如，InnoSer 的腫瘤 CRO 服務提供全面的PDX 小鼠模型，用於評估治療效果，使申辦者能夠在體內重現腫瘤異質性和治療反應。

同樣，LIDE Biotech 擁有全球最大的PDX 生物庫之一，擁有超過 1900個模型，涵蓋近 50 種癌症類型，為外部合作夥伴提供了一套多樣化的、特徵明確的異種移植模型，用於藥物篩檢和轉化研究。

策略聯盟也推動了這種外包趨勢。例如，2025年10月，Xenostart和Minerva Imaging擴大了雙方為期10年的合作，推出了一個完全整合的PDX放射性藥物開發平台。該平台結合了Xenostart的臨床註釋PDX庫和Minerva的分子影像和放射性核素治療專業知識以及CDMO能力，簡化了從藥物發現到臨床應用的整個流程。

隨著複雜的臨床前試驗成為腫瘤贊助商的標準外包策略，專門從事 PDX 模型的CRO 經歷高於市場平均水準的成長，鞏固了其在中國、新加坡和印度等地的區域領導地位，並推動了全球 PDX 模型市場需求的成長。

癌症負擔日益加重和篩檢的進步

推動全球患者來源異種移植（PDX）模型市場發展的關鍵趨勢是全球癌症發病率的上升和早期檢測技術的進步，這促使人們對具有生物學相關性的臨床前模型的需求不斷成長。根據世界衛生組織（WHO）預測，全球癌症病例數預計將從2022年的2,000萬例增加到2050年的3,500萬例，增幅達77%。

同樣，印度的癌症病例自1990年以來加倍，預計2025年將新增157萬例，2023年將有超過82萬人死亡。這主要是由於吸煙、飲酒、肥胖、缺乏運動和環境污染等因素造成的。這些地區最常見的癌症包括乳癌、肺癌、大腸癌、口腔癌和腎臟癌。此外，據預測，美國2025年將新增2041910例癌症病例，並有618120人死亡（NIH，2025），凸顯了對預測性臨床前模型的持續需求。

隨著癌症負擔的加重，早期檢測技術也取得了長足進步，包括用於肺癌的低劑量CT掃描、數位乳房斷層合成（3D乳房X光攝影）以及分析循環腫瘤DNA（ctDNA）和微量殘存疾病（MRD）的微創液態生物檢體。這些技術使得在更早期、更多樣化的階段識別腫瘤成為可能，擴大了可用於轉化研究的腫瘤範圍。

在亞太地區和中東及非洲等地區，PDX平台的應用加速，以將臨床前研究成果轉化為精準癌症治療方案。諸如ARPA-H斥資2500萬美元開展的居家癌症篩檢計畫等公共舉措推動這一趨勢，並刺激了對異質骨移植的需求，以評估亞型特異性治療方法。隨著癌症的可檢測性增強、多樣性增加以及臨床複雜性提高，PDX模型作為現代精準癌症治療研發的重要工具，其應用日益廣泛。

目錄

第1章 執行摘要

第2章 市場亮點

• 依類型分類的主要市場趨勢
• 依產品分類的主要市場趨勢
• 依小鼠模型分類的關鍵市場趨勢
• 依服務分類的主要市場趨勢
• 依應用分類的主要市場趨勢
• 依最終用戶分類的主要市場趨勢
• 依技術分類的主要市場趨勢

第3章 市場動態

• 宏觀經濟分析
• 市場趨勢
• 市場促進因素
• 市場機會
• 市場限制
• 年複合均成長率分析
• 影響分析
• 新興市場
• 技術藍圖
• 戰略框架

第4章 細分市場分析

• 依類型分類的市場規模及預測（2020-2035年）
• 依產品分類的市場規模及預測（2020-2035年）
• 依小鼠模型分類的市場規模及預測（2020-2035年）
• 依服務分類的市場規模及預測（2020-2035年）
• 依應用領域分類的市場規模及預測（2020-2035年）
• 依最終用戶分類的市場規模和預測（2020-2035年）
• 依技術分類的市場規模和預測（2020-2035年）
• 全球市場概覽
• 北美市場規模（2020-2035年）
• 拉丁美洲市場規模（2020-2035年）
• 亞太市場規模（2020-2035年）
• 歐洲市場規模（2020-2035年）
• 中東和非洲市場規模（2020-2035年）
• 需求與供給差距分析
• 貿易和物流限制
• 價格、成本和利潤率趨勢
• 市場滲透率
• 消費者分析
• 法規概述

第7章 競爭訊息

• 市場定位
• 市場占有率
• 與競爭對手的比較分析
• 主要企業的策略

第8章 公司簡介

• Charles River Laboratories
• Crown Bioscience
• The Jackson Laboratory（JAX）
• Champions Oncology
• Medicilon
• TheraIndx Lifesciences Pvt. Ltd.
• Noble Life Sciences Inc.
• Creative Biolabs Inc.
• BioDuro
• EPO Berlin-Buch GmbH
• WuXi AppTec
• XenTech
• Urosphere
• Oncodesign Services
• Pharmatest Services
• Inotiv
• GemPharmatech
• Altogen Biosystems
• Abnova Corporation
• Taconic Biosciences

第9章 關於

• 關於
• 調查方法
• 調查工作流程
• 諮詢服務
• 客戶
• 客戶評價
• 詢問

Patient-Derived Xenograft Model Market is anticipated to expand from $363.7 million in 2025 to $1,121.9 million by 2035, growing at a CAGR of approximately 12.1%. Rising Oncology Research & Drug Development Needs - High demand from pharmaceutical and biotech companies for predictive preclinical models drives growth. Companies seek diverse PDX models (solid tumors, hematologic cancers, pediatric cancers) for translational studies and therapy evaluation. For instance, Charles River offers 1,700+ PDX models covering 45+ cancer indications, supporting drug efficacy testing across multiple tumor types.

Availability of Specialized Models - The supply of PDX models is limited, particularly for low-passage tumors, rare cancer types, and humanized platforms. Challenges in sourcing donor tissue and successful engraftment restrict production capacity. For example, Crown Bioscience's HSC-PDX and Hera BioLabs' MiXeno(TM) PBMC-humanized models represent high-demand specialized models with limited availability.

Regulatory Compliance and Data Reliability - There is strong demand for PDX models that maintain high genetic and histological fidelity, provide reproducible results, and meet regulatory standards. Models with these attributes are preferred for IND-enabling studies and translational research. For instance, Oncodesign and Charles River offer fully characterized PDX models that ensure clinical relevance and regulatory compliance.

Technological Advancements and Automation - Adoption of AI, imaging technologies, and organoid-based in vitro assays is enhancing the predictive power and efficiency of PDX studies. For example, Charles River's AI-enabled virtual control groups and 3D organoid PDX platforms accelerate preclinical testing and reduce reliance on animal models.

Segment Overview

Based on tumor type, the patient-derived xenograft (PDX) model market is divided into Gastro-Intestinal Tumors, Respiratory Tumors, Gynecological Tumors, Hematological Malignancies, Central Nervous System Tumors, Dermatological Tumors, and Other Solid Tumors.

The respiratory tumor segment is one of the fastest-growing due to lung cancer's high global burden lung cancer was the most frequently diagnosed cancer worldwide in 2022 with about 2.48 million new cases and also the leading cause of cancer death.

This high incidence drives strong demand for PDX models in NSCLC research to study driver mutations and resistance mechanisms. For example, in 2024, UCL researchers deposited 44 NSCLC TRACERx PDX models via CancerTools.org, enabling studies on tumor evolution, heterogeneity, immune escape, and drug resistance, supporting the rising demand for translational PDX models in lung cancer.

The gastro-intestinal tumor segment also strongly contributes to PDX adoption, as colorectal cancer ranked third globally with approximately 1.93 million new cases in 2022 and pancreatic cancer had around 510,992 new cases, both representing substantial unmet clinical needs that benefit from PDX platforms that better preserve tumor heterogeneity than traditional models.

The Gastro-Intestinal tumor segment is driven by the growing availability of clinically relevant PDX models that enable high-fidelity preclinical testing. Key developments include Champions Oncology's gastric cancer PDXs, which preserve patient tumor biology, and Crown Bioscience's extensive GI PDX library, covering colorectal and gastric cancers.

Additionally, Charles River Laboratories' 2019 expansion of 79 GI PDX models and The Jackson Laboratory's clinically validated GI portfolio provide robust platforms for drug screening and biomarker research. These resources accelerate translational research, support precision oncology pipelines, and reinforce strong segment growth.

The hematological malignancies segment is driving PDX market growth due to the critical need for models that replicate human leukemia, lymphoma, and multiple myeloma biology. PDX platforms, such as the AML panels by Crown Bioscience (2017) and the extensive hematologic PDX collection at the Washington University PDX Development and Trial Center (2025, Siteman Cancer Center), enable preclinical drug testing, mechanism-of-resistance studies, and personalized therapy evaluation.

Geographical Overview

The North American patient-derived xenograft (PDX) model market is expanding due to the rapidly rising cancer burden and the corresponding demand for predictive, patient-relevant preclinical models. In 2024, the United States is projected to report approximately 2,001,140 new cancer cases and 611,720 cancer deaths, reflecting a record-high incidence driven by population aging, improved diagnostic coverage, and increased screening uptake, all of which enhance the need for more biologically faithful oncology research models.

The United States accounts for the largest share of the North American PDX model market, supported by its extensive biopharmaceutical research ecosystem, specialized contract research organizations (CROs), and strong oncology-focused R&D investments. According to the National Center for Science and Engineering Statistics (NCSES), in 2023, U.S. companies invested approximately $722 billion in R&D, including $43 billion (6%) in basic research and $110 billion (15%) in applied research, underscoring the sustained funding priorities that reinforce demand for translational platforms such as PDX models.

Asia-Pacific is expected to be the fastest-growing region during the forecast period. The Asia-Pacific patient-derived xenograft (PDX) model market is rapidly growing due to the region's high cancer burden and expanding oncology research. According to Pfizer, there are about 3.6 million males and 4.0 million females living with cancer in major Asian countries, with China alone accounting for 1.6 million males and 1.5 million females. China has established large PDX libraries for gastrointestinal, lung, liver, and esophageal cancers, accurately preserving tumor histology and drug response.

Japan utilizes the J-PDX Library, Fukushima Medical University, and universities like Kanazawa for breast cancer, leukemia, pancreatic cancer, and pediatric ALL, supporting personalized medicine and drug testing. India is emerging as a hub for PDX studies, with ACTREC developing models for TNBC and hormone receptor-positive breast cancer, TheraIndx providing PDX/CDX models, and Altogen Labs validating 10 lung cancer xenograft models in August 2024.

Australia uses PDX models at Children's Cancer Institute, MURAL, UNSW Sydney, WEHI, and Peter MacCallum Cancer Centre for prostate, breast, colorectal, and pediatric cancers. South Korea employs PDX models at CHA Bundang Medical Center and Yonsei University Severance Hospital for ovarian, gastric, and biliary tract cancers.

Singapore leverages NCCS, A*STAR IMCB, and NUS for liver and biliary tract cancers. Indonesia is developing PDX models for breast and other solid tumors to support translational research. Across the region, these initiatives reflect rising cancer prevalence and adoption of patient-relevant preclinical models, driving strong PDX demand.

Key Trends and Drivers

"Rising Outsourcing of PDX Models to CROs Accelerates Market Expansion -

increasing outsourcing of oncology preclinical research to contract research organizations (CROs) drive the market growth. As pharma and biotech pipelines widening in-house capacities and shifting sponsors toward partners with specialized PDX capabilities.

Outsourcing to CROs allows sponsors to access expertise, infrastructure, and scalable vivarium resources that many internal labs lack, while reducing costs and accelerating translational timelines. For example, InnoSer's oncology CRO services offer comprehensive PDX mouse models for evaluating therapeutic efficacy, enabling sponsors to recapitulate tumor heterogeneity and treatment responses in vivo.

Similarly, LIDE Biotech maintains one of the world's largest PDX biobanks with over 1,900+ models covering nearly 50 cancer types, providing outsourced partners access to diverse, well-characterized xenografts for drug screening and translational studies.

Strategic collaborations further illustrate this outsourcing trend for instance, in October, 2025, XenoSTART and Minerva Imaging expanded their decade-long partnership to deliver a fully integrated PDX-radiopharmaceutical drug development platform, combining XenoSTART's clinically annotated PDX repository with Minerva's molecular imaging, radionuclide therapy expertise, and CDMO capabilities to streamline discovery through clinical translation.

As complex preclinical studies become the default outsourcing strategy for oncology sponsors, CROs specializing in PDX models are achieving above-market growth, reinforcing regional leadership in hubs such as China, Singapore, and India and driving incremental demand across the global PDX models market.

Increasing Cancer Burden and Advanced Screening -

A key trend driving the global patient-derived xenograft (PDX) models market is the rising global cancer incidence coupled with advances in early detection technologies, which is intensifying demand for biologically relevant preclinical models. According to the World Health Organization (WHO), global cancer cases are projected to reach 35 million by 2050, a 77% increase from 20 million cases in 2022.

Similarly, In India, cancer cases have doubled since 1990, with 1.57 million new cases projected in 2025 and over 820,000 deaths in 2023, driven by tobacco and alcohol use, obesity, sedentary lifestyles, and environmental pollution. The most common cancers in these regions include breast, lung, colorectal, oral, and kidney cancers. Additionally, in the United States, 2,041,910 new cancer cases and 618,120 deaths are projected in 2025 (NIH, 2025), underscoring the ongoing need for predictive preclinical models.

The growing cancer burden is matched by advancements in early detection, including low-dose CT scans for lung cancer, digital breast tomosynthesis (3D mammography), and minimally invasive liquid biopsies that analyze circulating tumor DNA (ctDNA) or minimal residual disease (MRD). These technologies allow identification of tumors at earlier, more biologically diverse stages, expanding the range of tumors available for translational research.

Regions such as Asia-Pacific, the Middle East, and Africa are increasingly adopting PDX platforms to translate preclinical findings into precision oncology solutions, supported by public initiatives like ARPA-H's USD 25 million at-home multi-cancer screening program, which drives demand for xenografts to evaluate subtype-specific therapies. As cancer becomes more detectable, diverse, and clinically complex, accelerating the adoption of PDX models as essential tools in modern precision oncology research and drug development.

Research Scope

• Estimates and forecasts the overall market size across type, product, mice models, services, application, end user, technology, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Mice Models
• 2.4 Key Market Highlights by Services
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Technology

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Gastro-Intestinal Tumors
  • 4.1.2 Gynecological Tumors
  • 4.1.3 Respiratory Tumors
  • 4.1.4 Central Nervous System Tumors
  • 4.1.5 Hematological Malignancies
  • 4.1.6 Dermatological Tumors
  • 4.1.7 Other Solid Tumors
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Mice Models
  • 4.2.2 Rat Models
• 4.3 Market Size & Forecast by Mice Models (2020-2035)
  • 4.3.1 Nude (Athymic)
  • 4.3.2 NOD/SCID
  • 4.3.3 NSG
  • 4.3.4 Humanized Mice
• 4.4 Market Size & Forecast by Services (2020-2035)
  • 4.4.1 Model Creation & Expansion
  • 4.4.2 Model Characterization
  • 4.4.3 Cryopreservation
  • 4.4.4 Other Services
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Preclinical Research
  • 4.5.2 Biomarker Analysis
  • 4.5.3 Translational Research
  • 4.5.4 Biobanking
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Pharma & Biotechnology Companies
  • 4.6.2 CROs & CDMOs
  • 4.6.3 Academics & Research Institutes
• 4.7 Market Size & Forecast by Technology (2020-2035)
  • 4.7.1 Heterotopic (Subcutaneous) Implantation
  • 4.7.2 Orthotopic Implantation5 Regional Analysis
• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Mice Models
    • 5.2.1.4 Services
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Technology
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Mice Models
    • 5.2.2.4 Services
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Technology
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Mice Models
    • 5.2.3.4 Services
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Technology
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Mice Models
    • 5.3.1.4 Services
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Technology
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Mice Models
    • 5.3.2.4 Services
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Technology
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Mice Models
    • 5.3.3.4 Services
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Technology
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Mice Models
    • 5.4.1.4 Services
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Technology
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Mice Models
    • 5.4.2.4 Services
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Technology
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Mice Models
    • 5.4.3.4 Services
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Technology
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Mice Models
    • 5.4.4.4 Services
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Technology
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Mice Models
    • 5.4.5.4 Services
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Technology
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Mice Models
    • 5.4.6.4 Services
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Technology
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Mice Models
    • 5.4.7.4 Services
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Technology
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Mice Models
    • 5.5.1.4 Services
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Technology
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Mice Models
    • 5.5.2.4 Services
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Technology
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Mice Models
    • 5.5.3.4 Services
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Technology
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Mice Models
    • 5.5.4.4 Services
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Technology
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Mice Models
    • 5.5.5.4 Services
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Technology
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Mice Models
    • 5.5.6.4 Services
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Technology
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Mice Models
    • 5.6.1.4 Services
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Technology
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Mice Models
    • 5.6.2.4 Services
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Technology
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Mice Models
    • 5.6.3.4 Services
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Technology
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Mice Models
    • 5.6.4.4 Services
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Technology
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Mice Models
    • 5.6.5.4 Services
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Technology6 Market Strategy
• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Charles River Laboratories
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Crown Bioscience
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 The Jackson Laboratory (JAX)
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Champions Oncology
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Medicilon
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 TheraIndx Lifesciences Pvt. Ltd.
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Noble Life Sciences Inc.
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Creative Biolabs Inc.
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 BioDuro
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 EPO Berlin-Buch GmbH
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 WuXi AppTec
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 XenTech
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Urosphere
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Oncodesign Services
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Pharmatest Services
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Inotiv
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 GemPharmatech
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Altogen Biosystems
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Abnova Corporation
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Taconic Biosciences
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us